Current Chart When the markets are open the data is delayed by 20 minut- es, until 20 minutes after closing. Biotech-Stock Mailbag: Amgen, MiddleBrook (at TheStreet.com: Fri, 4 Jul 2008 11:59:44 Etc/GMT) SEATTLE GENETICS INC /WA Files SEC form 8-K, Entry into a Material Definitive Agreement (EDGAR Online: Thu, 3 Jul 2008 20:31:09 Etc/GMT) Coverage initiated on Seattle Genetics by UBS (Briefing.com: Thu, 19 Jun 2008 10:43:51 Etc/GMT) Seattle Genetics gets milestone payment (AP: Wed, 18 Jun 2008 13:36:33 Etc/GMT) Biotechnology company Seattle Genetics Inc. said Wednesday that it received a milestone payment from Genentech Inc. after that company filed an investigational new drug application for an antibody-drug conjugate using Seattle Genetics technology. Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration Triggered by Genentech's IND Filing (Business Wire: Wed, 18 Jun 2008 12:00:00 Etc/GMT) BOTHELL, Wash. Seattle Genetics, Inc. , announced today that it has achieved a milestone under its antibody-drug conjugate collaboration with Genentech, Inc. The milestone was triggered by Genentech's filing of an Investigational New Drug application with the U.S. Seattle Genetics Announces SGN-35 Plenary Presentation at International Conference on Malignant Lymphoma (Business Wire: Fri, 6 Jun 2008 13:00:00 Etc/GMT) SEATTLE Seattle Genetics, Inc. today announced that SGN-35 will be highlighted in an oral presentation during a plenary session on Saturday, June 7, 2008 at the International Conference on Malignant Lymphoma being held in Lugano, Switzerland. Seattle Genetics to Present at Upcoming Investor Conferences (Business Wire: Wed, 4 Jun 2008 13:00:00 Etc/GMT) BOTHELL, Wash. Seattle Genetics, Inc. announced today that management will present at two upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics' website, www.seattlegenetics.com, under the "news and investor information" section.

Seattle Genetics Reports Multiple Complete and Partial Responses with SGN-35 in Patients with Lymphoma (Business Wire: Tue, 3 Jun 2008 13:00:00 Etc/GMT) SEATTLE Seattle Genetics, Inc. today announced positive data from a phase I clinical trial of SGN-35, an antibody-drug conjugate , demonstrating multiple objective responses at well-tolerated doses in patients with Hodgkin lymphoma and other CD30-positive hematologic malignancies. Seattle Genetics Announces Initiation of SGN-40 Phase Ib Clinical Trial in Combination With Velcade for Multiple Myeloma (Business Wire: Mon, 2 Jun 2008 13:00:00 Etc/GMT) BOTHELL, Wash. Seattle Genetics, Inc. announced today that its collaborator, Genentech, Inc., has initiated a phase Ib clinical trial of SGN-40 in combination with Velcade® for patients with relapsed or refractory multiple myeloma. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma (PR Newswire: Sun, 1 Jun 2008 22:00:00 Etc/GMT) CuraGen Corporation today presented encouraging results from the ongoing Phase I/II study of CR011-vcMMAE for the treatment of unresectable Stage III or Stage IV melanoma. Seattle Genetics Announces Upcoming SGN-35 Presentation at the American Society of Clinical Oncology Annual Meeting (Business Wire: Fri, 16 May 2008 13:10:00 Etc/GMT) BOTHELL, Wash. Seattle Genetics, Inc. announced today that SGN-35 phase I clinical data will be presented during a poster discussion session at the 44th American Society of Clinical Oncology Annual Meeting being held May 30 to June 3, 2008 at the McCormick Place Convention Center in Chicago, Illinois. SEATTLE GENETICS INC /WA Files SEC form 10-Q, Quarterly Report (EDGAR Online: Fri, 9 May 2008 20:18:49 Etc/GMT) Seattle Genetics Earnings Call scheduled for 5:00 pm ET today (CCBN: Thu, 24 Apr 2008 21:00:00 Etc/GMT) SEATTLE GENETICS INC /WA Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and (EDGAR Online: Thu, 24 Apr 2008 20:31:53 Etc/GMT) Seattle Genetics Reports First Quarter 2008 Financial Results (Business Wire: Thu, 24 Apr 2008 20:15:00 Etc/GMT) BOTHELL, Wash. Seattle Genetics, Inc. today reported financial results for the first quarter of 2008. Q1 2008 Seattle Genetics Earnings Release - After Market Close (CCBN: Thu, 24 Apr 2008 11:07:26 Etc/GMT)

© 2007 stocksmakingthenews.com Powered by Yahoo! Finance